Development of TGF-β signalling inhibitors for cancer therapy

Nature Reviews Drug Discovery

Volumn 3, Issue 12, 2004, Pages 1011-1022

  Yingling, Jonathan M ^a   Blanchard, Kerry L ^a   Sawyer, J Scott ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ANTISENSE OLIGONUCLEOTIDE; AP 11014; AP 12009; CANCER VACCINE; FLUOROURACIL; GC 1008; GEFITINIB; IMATINIB; IMIDAZOPYRIDINE DERIVATIVE; LERDELIMUMAB; LISINOPRIL; LY 550410; LY 580276; METELIMUMAB; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY; NPC 30345; PROTEIN KINASE INHIBITOR; PYRAZOLOPYRIMIDINE DERIVATIVE; SB 505124; SD 093; SD 208; SUNITINIB; TEMOZOLOMIDE; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA ANTIBODY; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG;

CANCER; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CARCINOGENESIS; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; COLORECTAL CANCER; DEVELOPMENTAL BIOLOGY; DIABETIC NEPHROPATHY; DRUG DESIGN; DRUG PENETRATION; DRUG TARGETING; FIBROSIS; GLIOMA; HUMAN; LUNG NON SMALL CELL CANCER; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN FAMILY; REGULATORY MECHANISM; REVIEW; SCAR FORMATION; SIDE EFFECT; SIGNAL TRANSDUCTION; TUMOR IMMUNOLOGY;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG DESIGN; HUMANS; NEOPLASMS; SIGNAL TRANSDUCTION; TRANSFORMING GROWTH FACTOR BETA;

EID: 10444261212     PISSN: 14741776     EISSN: None     Source Type: Journal    
DOI: 10.1038/nrd1580     Document Type: Review

References (118)

1. Tsukazaki, T., Chiang, T. A., Davison, A. F., Attisano, L. & Wrana, J. L. SARA, a FYVE domain protein that recruits smad2 to the TGFβ receptor. Cell 95, 779 (1998).
2. Tang, Y. et al. Disruption of transforming growth factor-β signaling in ELF β-spectrin-deficient mice. Science 299, 574-577 (2003).
3. Shi, Y. & Massagué J. Mechanisms of TGF-β signaling from cell membrane to the nucleus. Cell 113, 685-700 (2003).
4. Derynck, R. & Zhang, Y. E. Smad-dependent and Smad-independent pathways in TGF-β family signaling. Nature 425 577-584 (2003).
5. Hassel, S. et al. Proteins associated with type II bone morphogenetic protein receptor (BMPR-II) and identified by two-dimensional gel electrophoresis and mass spectrometry. Proteomics 4, 1346-1358 (2004).
6. Yu, L., Hebert, M. C. & Zhang, Y. E. TGF-β receptor-activated d38 MAP kinase mediates smad-independent TGF-β responses. EMBO J. 21, 3749-3759 (2002).
7. Foletta, V. C. et al. Direct signaling by the BMP type II receptor via the cytoskeletal regulator LIMK1. J. Cell Biol. 162, 1089-1098 (2003).
8. Siegel, P. M. & Massagué, J. Cytostatic and apoptotic actions of TGF-β in homeostasis and cancer. Nature Rev. Cancer 3, 807-818 (2003).
9. Wakefield, F. M. & Roberts, A. B. TGF-β signaling: positive and negative effects on tumorigenesis. Curr. Opin. Gen. Dev. 12 22-29 (2002).
10. Dumont, N. & Arteaga, C. L. Targeting the TGF-β signaling network in human neoplasia. Cancer Call 3, 531-536 (2003).
11. Tang, B. et al. TGF-β switches from tumor suppressor to prometastatic factor in a model of breast cancer progression. J. Clin. Invest. 112, 1116-1124 (2003).
12. Cui, W. et al. TGFβ1 inhibits the formation of benign skin tumors, but enhances progression to invasive spindle carcinomas in transgenic mice. Cell 86, 531-542 (1996).
13. Oft, M., Akhurst, R. J. & Balmain, A. Metastasis is driven by sequential elevation of H-ras and Smad2 levels. Nature Cell Biol. 4, 487-494 (2002).
14. Thiery, J. P. Epithelial-mesenchymal transitions in tumour progression. Nature Rev. Cancer 2, 442-454 (2002).
15. Tian, F. et al. Reduction in Smad2/3 signaling enhances tumorigenesis but suppresses metastasis of breast cancer cell lines. Cancer Res. 63, 8284-8292 (2003).
16. Tian, F. et al. Smad-binding defective mutant of transforming growth factor β type I receptor enhances tumorigenesis but suppresses metastasis of breast cancer cell lines. Cancer Res. 64, 4523-4530 (2004).
17. Vega, S. et al. Snail blocks the cell cycle and confers resistance to cell death. Genes Dev. 18, 1131-143 (2004).
18. Yang, J. et al. Twist, a master regulator of morphogenesis plays an essential role in tumor metastass. Cell 117, 927-939 (2004).
19. Peinado, H., Quintanilla, M. & Cano, A. Transforming growth factor β-1 induces snail transcription factor in epithelial cell lines. J. Biol. Chem. 278, 21113-21123 (2003).
20. Bakin, A. V., Tomlinson, A. K., Bhowmick, N. A., Moses, H. L. & Arteaga, C. L. Phosphatidylinositol 3-kinase function is required for transforming growth factor β-mediated epithelial to mesenchymal transition and cell migration. J. Biol. Chem. 275, 36803-36810 (2000).
21. Brown, K. A. et al. Induction by transforming growth factor-β1 of epithelial to mesenchymal transition is a rare event in vitro. Breast Cancer Res. 6, R215-R231 (2004).
22. Zavadil, J., Cermak, L., Soto-Nieves, N. & Bõttinger, E. P. Integration of TGF-β/Smad and Jagged1/Notch signaling in epithelial-to-mesenchymal transition. EMBO J. 23, 1155-1165 (2004).
23. Muraoka, R. et al. Blockade of TGF-β inhibits mammary tumor cell viability, migration, and metastases. J. Clin. Invest. 109, 1551-1559 (2002).
24. Letterio, J. J. & Roberts, A. B. Regulation of immune responses by TGF-β. Annu. Rev. Immunol. 16, 137-161 (1998).
25. Kulkarni, et al. Transforming growth factor β1 null mutation in mice causes excessive inflammatory response and early death. Proc. Natl Acad. Sci. USA 90, 770-774.
26. Shull, et al. Targeted disruption of the mouse transforming growth factor-β1 gene results in mulitfocal inflammatory disease. Nature 359, 693-699.
27. Gorelik, L. & Flavell, R. A. Abrogation of TGF-β signaling in T cells leads to spontaneous T cell differentiation and autoimmune disease. Immunity 12, 171-181 (2000).
28. Levéen, P. et al. Induced disruption of the transforming growth factor β type II receptor gene in mice causes a lethal inflammatory disorder that is transplantable. Blood 100 560-568 (2002).
29. Gorelik, L. & Flavell, R. A. Immune-mediated eradication of tumors through the blockade of transforming growth factor-β signaling in T cells. Nature Med. 7, 1118-1122 (2001).
30. Inman, G. J., Nicolás, F. J. & Hill, C. S. Nucleocytoplasmic shuttling of Smads 2, 3, and 4 permits sensing of TGF-β receptor activity. Mol. Cell 10, 283-294 (2002).
31. Conery, A. et al. Akt interacts directly with Smad3 to regulate the sensitivity to TGF-β-induced apoptosis. Nature Cell Biol. 6, 366-372 (2004).
32. Remy, I., Montmarquette, A. & Michnick, S. W. PKB/Akt modulates TGF-β signaling through a direct interaction with Smad3. Nature Cell Biol. 6, 358-365 (2004).
33. Felici, A. et al. TLP, a novel modulator of TGF-β signaling, has opposite effects on Smad2- and Smad3-dependent signaling. EMBO J. 22, 4465-4477 (2003).
34. InK4B. Mol. Cell 9, 133-143 (2002).
35. Seoane, J., Le, H. V, Shen, L., Anderson, S. A. & Massague, J. Integration of Smad and forkhead pathways in the control of neuroepithelial and glioblastoma cell proliferation. Cell 117 211-223 (2004).
36. Matsuura, I. et al. Cyclin-dependent kinases regulate the anti-proliferative function of Smads. Nature 430, 226-231 (2004).
37. Bai, Y., Yang, C., Hu, K., Elly, C. & Liu, Y.-C. Itch E3 ligase-mediated regulation of TGF-β signaling by modulating Smad2 phosphorylation. Mol. Cell 15, 825-831 (2004).
38. Engel, M. E., McDonnell, M. A., Law, B. K. & Moses, H. L. Interdependent SMAD and JNK signaling in transforming growth factor-β-mediated transcription. J. Biol. Chem. 274, 37413-37420 (1999).
39. Brown, J. D., DiChiara, M. R., Anderson, K. R., Gimbrone, M. A. & Topper, J. N. MEKK-1, a component of the stress (stress-activated protein kinase/c-Jun N-terminal kinase) pathway, can selectively activate Smad2-mediated transcriptional activation in endothelial cells. J. Biol. Chem. 274, 8797-8805 (1999).
40. Verrecchia, F., Tacheau, C., Wagner, E. F. & Mauviel, A. A central role for the JNK pathway in mediating the antagonistic activity of pro-inflammatory cytokines against transforming growth factor-β-driven SMAD3/4-specific gene expression. J. Biol. Chem. 278, 1585-1593 (2003).
41. Dennler, S., Prunier, C., Ferrand, N., Gauthier, J.-M. & Atfi A. c-Jun inhibits transforming growth factor β-mediated transcription by repressing Smad3 transcriptional activity. J. Biol. Chem. 275 28858-28865 (2000).
42. Ventura, J.-J., Kennedy, N. J., Havell, R. A. & Davis, R. J. JNK regulates autocrine expression of TGF-β1. Mol. Cell 15, 269-278 (2004).
43. Maeda, S., Hayashi, M., Komiya, S., Imamura, T. & Miyazono, K. Endogenous TGF-β signaling suppresses maturation of osteoblastic mesenchymal cells. EMBO J. 23, 552-563 (2004).
44. Peng, S. B. et al. Kinetic characterization of novel pyrazole TGF-β receptor I kinase inhibitors and their blockade of epithelial to mesenchymal transition. Biochemistry (in the press).
45. Wang, S. & Hirschberg, R. Bone morphogenetic protein-7 signals opposing transforming growth factor β in mesangial cells. J. Biol. Chem. 279, 23200-23206 (2004).
46. Zeisberg, M. et al. BMP-7 counteracts TGF-β1-induced epithelial-to-mesenchymal transition and reverses chronic renal injury. Nature Med. 9, 964-968 (2003).
47. Yang, Y. A. et al. Lifetime exposure to a soluble TGF-β antagonist protects mice against metastasis without adverse side effects. J. Clin. Invest. 109, 1607-1615 (2002).
48. Bandyopadhyay, A. et al. Antitumor activity of a recombinant soluble βglycan in human breast cancer xenograft. Cancer Res. 62, 4690-4695 (2002).
49. Yin, J. J. et al. TGF-β signaling blockade inhibits PTHrP secretion by breast cancer cells and bone metastases development. J. Clin. Invest. 103, 197-206 (1999).
50. Areaga, C. L. et al. Anti-transforming growth factor (TGF)-β antibodies inhibit breast cancer cell tumorigenicity and increase mouse spleen natural killer cell activity. J. Clin. Invest. 92, 2569-2576 (1993).
51. Muraoka, R. S. et al. Increased malignancy of neu-induced mammary tumors overexpressing active transforming growth factor β1. Mol. Cell. Biol. 23, 8691-8703 (2003).
52. Siegel, P. M., Shu, W., Cardiff, R. D., Muller, W. J. & Massagué, J. Transforming growth factor β signaling impairs neu-induced mammary tumorigenesis while promoting pulmonary metastasis. Proc. Natl Acad. Sci. USA 100, 8430-8435 (2003).
53. Robertson, A. L. et al. Disruption of TGF-β signaling in T cells accelerates atherosclerosis. J. Clin. Invest. 112, 1342-1350 (2003).
54. Chang, H., Brown C. W. & Matzuk, M. M. Genetic analysis of the mammalian transforming growth factor-β superfamily. Endocr. Rev. 23, 787-823 (2002).
55. Yang, X. et al. TGF-β/Smad3 signals repress chondrocyte hypertrophic differentiation and are required for maintaining articular cartilage. J. Cell Biol. 153, 35-46 (2001).
56. Brown, C. B., Boyer, A. S., Runyan, R. B. & Barnett, J. V. Requirement of Type III TGF-β receptor for endocardial cell transformation in the heart. Science 283, 2080-2082 (1999).
57. 2-knockout mice. Circulation 103, 2745-2752 (2001).
58. Ruzek, M. C. et al. Minimal effects on immune parameters following chronic anti-TGF-β monoclonal antibody administration to normal mice. Immunopharmacol. Immunotoxicol. 25, 235-257 (2003).
59. Xie, W. et al. Alterations of smad signaling in human breast carcinoma are associated with poor outcome: a tissue microarray study. Cancer Res. 62, 497-505 (2002).
60. Huntley, S. P. et al. Attenuated type II TGF-β receptor signaling in human malignant oral keratinocytes induces a less differentiated and more aggressive phenotype that is associated with metastatic dissemination. Int. J. Cancer 110, 170-176 (2004).
61. Bottinger, E. P., Jakubczak, J. L., Haines, D. C., Bagnall, K. & Wafefield, L. M. Transgenic mice overexpressing a dominant-negative mutant type II transforming growth factor β receptor show enhanced tumorigenesis in the mammary gland and lung in response to the carcinogen 7,12-dimethylbenz-[a]-anthracene. Cancer Res. 57, 5564-5570 (1997).
62. Kanzler, S. et al. Hepatocellular expression of a dominant-negative mutant TGF-β type II receptor accelerates chemically induced hepatocarcinogenesis. Oncogene 20, 5015-5024 (2001).
63. Im, Y.-H. et al. Heterozygous mice for the transforming growth factor β type II receptor gene have increased susceptibility to hepatocellular carcinogenesis. Cancer Res. 61, 6665-6668 (2001).
64. Gorska, A. E. et al. Transgenic mice expressing a dominant-negative mutant type II transforming growth factor-β receptor exhibit impaired mammary development and enhanced mammary tumor formation. Am. J. Path. 163, 1539-1549 (2003).
65. Chytil, A., Magnuson, M. A., Wright, C. V. & Moses, H. L. Conditional inactivation of the TGF-β type II receptor using Cre:Lox. Genesis 32, 73-75 (2002).
66. Bhowmick, N. A. et al. TGF-β signaling in fibroblasts modulates the oncogenic potential of adjacent epithelia. Science 303, 848-851 (2004).
67. Biswas, S. et al. Transforming growth factor 3 receptor type II inactivation promotes the establishment and progression of colon cancer. Cancer Res. 64, 4687-4692 (2004).
68. Harari, D. & Yarden, Y. Molecular mechanisms underlying ErbB2/HER2 action in breast cancer. Oncogene 19, 6102-6114 (2000).
69. Yarden, Y. & Sliwkowski, M. X. Untangling the ErbB signaling network. Nature Rev. Mol. Cell Biol. 2, 127-137 (2001).
70. Seton-Rogers, S. E. et al. Cooperation of the ErbB2 receptor and transforming growth factor β in induction of migration and invasion in mammary epithelial cells. Proc. Natl Acad. Sci. USA 101, 1257-1262 (2004).
71. Ueda, Y. et al. Overexpression of HER2 (erbB2) in human breast epithelial cells unmasks transforming growth factor β-induced cell motility. J. Biol. Chem. 279, 24505-24513 (2004).
72. Mead, A. L., Wong, T. T., Cordeiro, M. F., Anderson, I. K. & Khaw, P. T. Evaluation of anti-TGF-β2 antibody as a new postoperative anti-scarring agent in glaucoma surgery. Invest. Ophthalmol. Vis. Sci. 44, 3394-3401 (2003).
73. Mealy, N. E. & Bayés, M. Lerdelimumab. Drugs Fut. 28, 320-322 (2003).
74. Benigni, A. et al. Add-on anti-TGF-β antibody to ACE inhibitor arrests progressive diabetic nephropathy in the rat. J. Am. Soc. Nephrology 14, 1816-1824 (2003).
75. Fakhrai, H. et al. Eradication of established intracranial rat gliomas by transforming growth factor β antisense gene therapy. Proc. Natl Acad. Sci. USA 93, 2909-2914 (1996).
76. Liau, L. M., Fakhrai, H. & Black, K. L. Prolonged survival of rats with intracranial C6 gliomas by treatment with TGF-β antisense gene. Neurol. Res. 20, 742-747 (1998).
77. Bogdahn, U. et al. Specific therapy for high-grade glioma by convection-enhanced delivery of the TGF-β2 specific antisense oligonucleotide AP 12009. Am. Soc. Clin. Oncol. Ann. Meet. Abstract 1514 (2004).
78. Schlingensiepen, K.-H. et al. The TGF-β1 antisense oligonucleotide AP 11014 for the treatment of non-small cell lung, colorectal and prostate cancer: preclinical studies. Am. Soc. Clin. Oncol. Ann. Meet. Abstract 3132 (2004).
79. Laping, N. J. ALK5 in renal disease. Curr. Opin. Pharm. 3, 204-208 (2003).
80. Singh, J. et al. Transforming the TGF-β pathway: convergence of distinct lead generation strategies on a novel kinase pharmacophore for TβRI (ALK5). Curr. Opin. Drug Disc. Dev. 7 437-445 (2004).
81. Sawyer, J. S. et al. Synthesis and activity of new aryl- and heteroaryl-substituted 5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole inhibitors of the transforming growth factor-β type I receptor kinase domain. BioMed. Chem. Lett. 14, 3581-3584 (2004).
82. Byfield, S. D., Major, C., Laping, N. & Roberts, A. SB-505124 is a selective inhibitor of transforming growth factor-β type I receptors ALK4, ALK5, and ALK7. Mol. Pharmacol. 65, 744-752 (2004).
83. Lee, W. C. et al. Preparation of (pyridinyl)(pyrimidinyl) imidazo[1,2-a]pyridines as TGFβ receptor type I antagonists for treatment of fibrotic disorders and tumors. WO Patent 2004021989 (2004).
84. Gellibert, F. et al. Identification of 1,5-naphthyridine derivatives as a novel series of potent and selective TGF-β type I receptor inhibitors. J. Med. Chem. 47, 4494-4506 (2004).
85. Sawyer, J. S. et al. Synthesis and activity of new aryl- and heteroaryl-substituted pyrazole inhibitors of the transforming growth factor-β type I receptor kinase domain. J. Med. Chem. 46 3953-3956 (2003).
86. Singh, J. et al. Successful shape-based virtual screening: the discovery of a potent inhibitor of the type I TFGβ receptor kinase (TβRI). BioMed. Chem. Lett. 13, 4355-4359 (2003).
87. Beight, D. W. et al. Preparation of pyrazolopyridines as TGF-β signal transduction inhibitors useful against cancer and other diseases. WO Patent 2004026871 (2004).
88. Blumberg, L. C. & Munchhof, M. J. Preparation of 2-(triazolyl)pyridines and related compounds as transforming growth factor (FGF) inhibitors for the treatment of cancer and fibrotic diseases. WO Patent 2004026307(2004).
89. Chakravarty, S. et al. Preparation of quinazolines as p38-β kinase and TGF-β inhibitors. WO Patent 2000012497 (2000).
90. Munchhof, M. J. Preparation of ureidoisothiazolecarboxamides as inhibitors of the transforming growth factor (TGF-β) signaling pathway. WO Patent 2004147574 (2004).
91. Huse, M. et al. The TGFβ receptor activation process: an inhibitor- to substrate-binding switch. Mol. Cell 8, 671-682 (2001).
92. Callahan, J. E. et al. Identification of novel inhibitors of the transforming growth factor β1 (TGF-β1) type 1 receptor (ALK5). J. Med. Chem. 45, 999-1001 (2002).
93. Ge, R. et al. Selective inhibitors of type I receptor kinase block cellular transforming growth factor-β signaling. Biochem. Pharmaccl. 68, 41-50 (2004).
94. Subramanian, G. et al. Targeting endogenous transforming growth factor β receptor signaling in SMAD4-dificient human pancreatic carcinoma cells inhibits their invasive phenotype. Cancer Res. 64, 5200-5211 (2004).
95. Uhl, M. et al. SD-208, a novel transforming growth factor-β receptor I kinase inhibitor, inhibits growth and invasiveness and enhances immunogenicity of murine and human glioma cells in vitro and in vivo. Cancer Res. 64, 7954-7961 (2004).
96. Eisenhauer, E. A., O'Dwyer, P. J., Christian, M. & Humphrey, J. S. Phase I clinical trial design in cancer drug development. J. Clin. Oncol. 18, 684-692 (2000).
97. Therasse, P. et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J. Natl Cancer Inst. 92, 205-216 (2000).
98. Marsoni, S. & Wittes, R. Clinical development of anticancer agents - a National Cancer Institute perspective. Cancer Treat. Rep. 68, 77-85 (1984).
99. Eisenhauer, E. A. Phase I and II trials of novel anti-cancer agents: endpoints, efficacy and existentialism. The Michel Clavel Lecture, held at the 10th NCI-EORTC Conference on New Drugs in Cancer Therapy, Amsterdam, 16-19 June 1998. Ann. Oncol. 9, 1047-1052 (1998)
100. Colburn, W. A. Biomarkers in drug discovery and development: from target identification through drug marketing. J. Clin. Pharmacol. 43, 329-341 (2003).
101. Arteaga, C. L. & Baselga, J. Tyrosine kinase inhibitors: why does the current process of clinical development not apply to them? Cancer Cell 5, 525-531 (2004).
102. Vogel, C. L. et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J. Clin. Oncol. 20, 719-726 (2002).
103. Slamon, D. J. et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. 344, 783-792 (2001).
104. Gorre, M. E. et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 293, 876-880 (2001).
105. Lynch, T. J. et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 350 2129-2139 (2004).
106. Paez, J. G. et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304, 1497-1500 (2004).
107. Shariat, S. Preoperative plasma levels of TGF-β1 strongly predict progression in patients undergoing radical prostatectomy. J. Clin. Oncol. 19, 2856-2864 (2001).
108. Wikstrom, P, et al. TGF-β1 is associate with angiogenesis, metastasis, and poor clinical outcome in prostate cancer. Prostate 37, 19-29 (1998).
109. Rich, J. N. The role of transforming growth factor-β in primary brain tumors. Front. Biosci. 8, e245-260 (2003).
110. Li, H. Y. et al. Novel and potent transforming growth factor β type I receptor kinase domain inhibitor: 7-amino 4-(2-pyridin-2-yl-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)-quinolines. BioMed. Chem. Lett. 14, 3585-3588 (2004).
111. Inman, G. J. et al. SB-431542 is a potent and specific inhibitor of transforming growth factor-β superfamily type I activin receptor like kinase (ALK) receptors ALK4, ALK5, and ALK7. Mol. Pharm. 62, 65-74 (2002).
112. Hjelmeland, M. D. et al. SB-431542, a small molecule transforming growth factor-β-receptor antagonist, inhibits human glioma cell line proliferation and motility. Mol. Cancer Ther. 3, 737-745 (2004).
113. Yingling, J. M. et al. Dihydropyrrolopyrazoles as TGF-β receptor kinase inhibitors for cancer therapy. Eur. J. Cancer 2 (Suppl.), 97 (2004).
114. Sebolt-Leopold, J. S. Development of anticancer drugs targeting the MAP kinase pathway. Oncogene 19, 6594-6599(2000).
115. Traxler, P. et al. AEE788: a dual family epidermal growth factor receptor/Erbβ and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity. Cancer Res. 64, 4931-4941 (2004).
116. Mendel, D. B. et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin. Cancer Res. 9, 327-337 (2003).
117. Morimoto, A. M. et al. Gene expression profiling of human colon xenograft tumors following treatment with SU11248, a multitargeted tyrosine kinase inhibitor. Oncogene 23, 1618-1626 (2004).
118. Bissel, M. J. Putting tumours in context. Nature Rev. Cancer 1, 46-54 (2001).